centuri
seen
global
spread
two
previous
unknown
coronavirus
novemb
first
known
case
sever
acut
respiratori
syndrom
sar
occur
foshan
new
case
emerg
mainland
china
februari
case
report
around
onethird
health
care
individu
infect
subsequ
travel
spread
outbreak
hong
vietnam
canada
sever
march
establish
network
laboratori
determin
caus
agent
sar
remark
global
effort
led
identif
sar
coronaviru
sarscov
earli
april
juli
total
report
case
includ
death
infect
detect
sar
pandem
declar
five
addit
sar
case
result
zoonot
transmiss
occur
decemb
ref
human
sar
case
detect
sinc
measur
infect
control
rather
medic
intervent
end
sar
pandem
howev
certain
sarscovlik
virus
found
bat
recent
shown
abl
infect
human
cell
without
prior
indic
sar
could
reemerg
june
year
first
emerg
sarscov
man
saudi
arabia
die
acut
pneumonia
renal
failur
novel
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
isol
cluster
case
sever
respiratori
diseas
occur
april
hospit
jordan
retrospect
diagnos
cluster
three
case
mer
uk
identifi
septemb
ref
merscov
continu
emerg
spread
countri
outsid
arabian
peninsula
result
travel
infect
person
often
import
mer
case
result
nosocomi
transmiss
may
singl
person
return
middl
east
start
nosocomi
outbreak
mer
south
korea
involv
hospit
april
confirm
case
mer
includ
death
review
highlight
pandem
epidem
potenti
emerg
coronavirus
discuss
current
knowledg
biolog
sarscov
merscov
includ
transmiss
pathogenesi
develop
medic
countermeasur
key
featur
virus
domin
nosocomi
transmiss
pathogenesi
driven
combin
viral
replic
lower
respiratori
tract
aberr
host
immun
respons
sever
potenti
treatment
sar
mer
identifi
anim
vitro
model
includ
smallmolecul
proteas
inhibitor
neutral
antibodi
inhibitor
host
immun
respons
howev
efficaci
data
human
clinic
trial
lack
need
move
potenti
countermeasur
forward
sarscov
merscov
belong
coronaviru
genu
coronavirida
famili
larg
positivesens
rna
genom
kb
kb
respect
fig
similarli
virus
order
nidoviral
sarscov
merscov
uniqu
code
strategi
twothird
viral
rna
translat
two
larg
polyprotein
remaind
viral
genom
transcrib
nest
set
subgenom
fig
two
polyprotein
encod
nonstructur
protein
make
viral
complex
polyprotein
cleav
two
proteas
papainlik
proteas
plpro
correspond
main
proteas
proteas
correspond
nsp
rearrang
membran
deriv
rough
endoplasm
reticulum
rer
doublemembran
vesicl
viral
replic
transcript
one
uniqu
featur
coronavirus
exoribonucleas
exon
function
ref
provid
proofread
capabl
requir
maintain
larg
rna
genom
without
accumul
detriment
sarscov
merscov
transcrib
subgenom
rna
respect
encod
four
structur
protein
spike
envelop
e
membran
nucleocapsid
n
well
sever
accessori
protein
involv
viral
replic
interfer
host
innat
immun
respons
unknown
poorli
understood
function
envelop
spike
glycoprotein
bind
cellular
receptor
angiotensinconvert
enzym
sarscov
dipeptidyl
peptidas
membran
fusion
either
directli
host
cell
membran
endosom
membran
viral
rna
genom
releas
cytoplasm
rna
uncoat
allow
translat
two
polyprotein
transcript
subgenom
rna
replic
viral
genom
fig
newli
form
envelop
glycoprotein
insert
rer
golgi
membran
genom
rna
nucleocapsid
protein
combin
form
nucleocapsid
viral
particl
bud
intermedi
compart
ergic
virioncontain
vesicl
subsequ
fuse
plasma
membran
releas
first
indic
sourc
sarscov
detect
viru
mask
palm
civet
raccoon
dog
detect
antibodi
viru
chines
ferret
badger
liveanim
market
shenzhen
howev
anim
incident
host
evid
circul
sarscovlik
virus
palm
civet
wild
breed
rather
bat
reservoir
wide
varieti
coronavirus
includ
sarscovlik
merscovlik
fig
thu
search
reservoir
merscov
initi
focus
bat
serolog
survey
dromedari
camel
oman
canari
island
show
high
preval
merscovneutr
antibodi
addit
merscov
rna
detect
swab
collect
dromedari
camel
farm
qatar
link
two
human
case
mer
infecti
viru
isol
dromedari
camel
saudi
arabia
serolog
evid
circul
merscovlik
viru
dromedari
camel
obtain
middl
east
eastern
africa
northern
africa
date
back
far
ref
dromedari
camel
saudi
arabia
harbour
sever
viral
genet
includ
caus
human
outbreak
taken
togeth
data
strongli
point
role
dromedari
camel
reservoir
merscov
ubiqu
infect
dromedari
camel
close
human
result
continu
zoonot
transmiss
may
explain
merscov
continu
caus
infect
human
wherea
sarscov
without
continu
presenc
infect
intermedi
host
rel
infrequ
interact
caus
infect
human
humantohuman
transmiss
sarscov
merscov
occur
mainli
nosocomi
transmiss
mer
case
individu
outbreak
link
hospit
similar
observ
made
sar
transmiss
famili
member
occur
mer
case
sar
case
transmiss
merscov
patient
common
rout
infect
case
wherea
sarscov
infect
health
care
worker
infect
patient
frequent
predomin
nosocomi
transmiss
probabl
due
fact
substanti
viru
shed
occur
onset
patient
alreadi
seek
medic
analysi
hospit
surfac
treatment
patient
mer
show
ubiquit
presenc
viral
rna
environ
sever
day
patient
longer
test
moreov
mani
patient
sar
mer
infect
super
sever
strategi
consid
treat
infect
merscov
tabl
sarscov
includ
use
antibodi
ifn
inhibitor
viral
host
proteas
hostdirect
therapi
current
therapi
absenc
clinic
proven
effect
antivir
therapi
sarscov
merscov
patient
mainli
receiv
support
care
often
supplement
differ
combin
drug
variou
type
ifn
given
patient
mer
saudi
typic
combin
broadspectrum
antibiot
oxygen
efficaci
treatment
sarscov
merscov
infect
current
remain
unclear
addit
treatment
mer
typic
start
late
diseas
stage
immunopatholog
predomin
antivir
drug
like
provid
littl
benefit
ribavirin
use
frequent
sar
outbreak
often
combin
corticosteroid
antiinflammatori
also
given
usual
combin
immunoglobulin
thymosin
stimul
develop
cell
small
number
case
combin
none
treatment
test
clinic
trial
make
difficult
assess
efficaci
fact
retrospect
analysi
yield
treatment
combin
clearli
effect
moreov
data
patient
contradictori
whether
ribavirin
use
alon
provid
benefit
possibl
even
vitro
coronavirus
lower
sensit
ribavirin
virus
delet
sequenc
increas
sensit
coronavirus
ribavirin
howev
underli
mechan
unclear
relat
proofread
function
ref
therefor
ribavirin
consid
combin
antivir
treatment
although
ifn
effect
merscov
effect
human
yet
prove
effect
ifn
increas
vitro
ribavirin
combin
use
two
drug
reduc
diseas
sever
rhesu
macaqu
model
potenti
side
effect
treatment
fatigu
depress
anaemia
inhibit
use
firstlin
treatment
mer
gener
administ
patient
condit
start
deterior
exampl
one
studi
five
patient
infect
merscov
indic
surviv
follow
ribavirin
therapi
howev
therapi
start
day
separ
studi
found
improv
surviv
day
mer
diagnosi
start
treatment
day
third
studi
combin
ribavirin
ribavirin
improv
surviv
howev
patient
year
old
preexist
renal
singl
case
ribavirin
start
shortli
admiss
hospit
patient
start
improv
day
admiss
made
complet
potent
inhibitor
merscov
replic
vitro
type
improv
outcom
diseas
observ
common
marmoset
challeng
thu
type
ifn
use
treatment
human
reconsid
usual
use
furthermor
ribavirin
andor
ifn
test
clinic
trial
determin
efficaci
mer
treatment
establish
treatment
protocol
addit
antivir
treatment
proteas
inhibitor
lopinavir
ritonavir
use
combin
treat
infect
hiv
improv
outcom
patient
sar
combin
ribavirin
compar
patient
treat
ribavirin
lopinavir
show
clear
antivir
activ
merscov
thu
rare
use
patient
mer
howev
lopinavir
ritonavir
improv
outcom
common
marmoset
treatment
initi
hour
infect
thu
test
lopinavir
ritonavir
clinic
trial
patient
mer
reconsid
one
patient
receiv
pegyl
ribavirin
lopinavir
ritonavir
combin
undetect
level
merscov
blood
day
initi
therapi
howev
patient
combin
ribavirin
lopinavir
ritonavir
also
use
mer
treatment
south
korea
efficaci
data
yet
avail
howev
three
case
report
indic
recoveri
five
seven
patient
treat
plpro
essenti
cleavag
viral
polyprotein
distinct
cellular
proteas
ideal
drug
target
particular
plpro
involv
viral
replic
ifn
antagon
inde
antivir
druglik
molecul
develop
plpro
aid
rapid
report
crystal
structur
plpro
initi
identifi
drugabl
target
sarscov
recent
note
compound
target
plpro
sarscov
also
activ
plpro
merscov
exampl
inhibit
merscov
sarscov
howev
efficaci
molecul
yet
test
vivo
mycophenol
acid
also
inhibit
replic
merscov
inhibit
effect
new
coronavirus
like
emerg
bat
proteas
inhibitor
design
bat
coronavirus
goal
develop
univers
antivir
compound
emerg
zoonot
coronavirus
approach
yield
inhibitor
tylonycteri
bat
coronaviru
close
relat
inhibitor
name
inde
inhibit
merscov
replic
similarli
peptidomimet
target
inhibit
merscov
pipistrellu
bat
coronaviru
also
identifi
yet
progress
beyond
vitro
sever
drug
approv
use
human
shown
inhibit
replic
merscov
vitro
notabl
chloroquin
chlorpromazin
loperamid
cyclosporin
although
mechan
action
unknown
benefit
cyclosporin
patient
debat
owe
immunosuppress
effect
drug
although
cyclophilin
inhibitor
result
immunosuppress
avail
activ
merscov
yet
test
antibodi
plasma
therapi
plasma
convalesc
patient
andor
antibodi
therapi
lead
propos
treatment
mer
sever
potenti
advantag
approach
exampl
case
number
increas
pool
survivor
becom
larger
provid
individu
suffici
high
antibodi
titr
will
abl
donat
plasma
lowtech
reason
safe
treatment
option
furthermor
gener
monoclon
antibodi
use
human
well
establish
fairli
straightforward
path
safeti
efficaci
test
howev
date
report
use
convalesc
plasma
none
use
monoclon
antibodi
treatment
acut
sever
respiratori
diseas
human
post
hoc
metaanalysi
studi
either
sar
sever
influenza
found
signific
reduct
pool
odd
mortal
convalesc
plasma
howev
studi
design
rate
low
low
qualiti
gener
lack
control
group
moderatetohigh
risk
bia
suggest
properli
design
clinic
trial
convalesc
plasma
use
sever
respiratori
infect
potent
monoclon
antibodi
neutral
merscov
spike
protein
vitro
howev
except
vivo
data
relat
use
convalesc
plasma
monoclon
antibodi
treatment
mer
current
lack
serum
hightitr
dromedari
camel
decreas
merscov
load
lung
mice
transduc
human
ref
human
polyclon
antibodi
spike
protein
gener
vaccin
transchromosom
bovin
treatment
antibodi
reduc
viral
titr
lung
mice
treatment
administ
hour
challeng
mice
also
treat
human
neutral
monoclon
antibodi
direct
receptorbind
domain
merscov
spike
protein
day
merscov
challeng
treatment
also
decreas
viral
titr
neutral
antibodi
obtain
convalesc
patient
produc
human
neutral
monoclon
antibodi
also
provid
benefit
mice
express
human
challeng
human
neutral
monoclon
antibodi
reduc
merscov
replic
lung
rabbit
follow
prophylact
therapeut
treatment
rhesu
macaqu
human
monoclon
antibodi
day
challeng
result
reduc
lung
studi
viral
replic
complet
inhibit
patholog
alter
lung
despit
therapi
furthermor
none
studi
address
potenti
emerg
escap
mutant
vivo
altern
antibodi
target
region
bind
spike
protein
could
use
prevent
entri
merscov
approach
success
howev
whether
treatment
would
feasibl
would
substanti
advers
effect
human
remain
determin
hostdirect
therapi
hostdirect
strategi
also
limit
viral
replic
exampl
spike
protein
sarscov
cleav
cathepsin
b
cathepsin
l
transmembran
proteas
serin
possibl
host
inhibit
host
serin
proteas
camostat
reduc
entri
sarscov
increas
surviv
mous
howev
target
host
proteas
like
result
undesir
side
effect
target
viral
proteas
anoth
underappreci
strategi
attenu
detriment
host
respons
develop
treatment
would
requir
thorough
understand
host
respons
involv
acut
lung
injuri
ard
process
unfortun
poorli
understood
moment
nonetheless
vitro
studi
limit
studi
anim
model
respiratori
virus
shown
anaphylatoxin
import
develop
acut
lung
injuri
block
anaphylatoxin
reduc
lung
chang
gene
express
vitro
merscov
infect
use
predict
potenti
effect
drug
one
drug
predict
efficaci
kinas
inhibitor
modestli
inhibit
sarscov
merscov
replic
follow
treatment
cell
prior
infect
treatment
infect
inhibit
replic
sarscov
vaccin
vaccin
could
use
prevent
infect
reduc
diseas
sever
viral
shed
therebi
transmiss
thu
help
control
mer
outbreak
sever
vaccin
strategi
develop
sarscov
test
anim
inactiv
viru
liveattenu
viru
viral
vector
subunit
vaccin
recombin
protein
dna
similar
approach
use
develop
experiment
merscov
date
three
merscov
vaccin
evalu
nonhuman
primat
one
studi
rhesu
macaqu
prime
dna
encod
spike
protein
follow
boost
spike
dna
recombin
protein
consist
spike
subunit
contain
receptorbind
domain
prime
boost
subunit
protein
approach
reduc
patholog
chang
lung
function
anim
infect
merscov
week
last
moreov
three
vaccin
recombinantli
express
protein
contain
receptorbind
domain
spike
protein
reduc
viral
load
lung
patholog
rhesu
macaqu
infect
week
last
three
dna
vaccin
construct
encod
fulllength
spike
sequenc
reduc
viral
load
patholog
lung
challeng
merscov
week
last
one
concern
vaccin
human
vaccinemedi
enhanc
diseas
process
diseas
follow
infect
sever
vaccin
individu
unvaccin
individu
although
observ
small
subset
vaccin
studi
carri
yet
observ
publish
merscov
vaccin
studi
import
concern
moreov
unclear
vaccin
merscov
healthi
individu
seem
littl
risk
sever
diseas
older
patient
patient
underli
diseas
highest
risk
sever
mer
would
import
target
popul
howev
vaccin
patient
problemat
owe
poor
immun
respons
establish
influenza
addit
vaccin
peopl
high
risk
exposur
merscov
health
care
worker
slaughterhous
worker
camel
herder
